| Literature DB >> 35755951 |
Stephen J Carter1, Marissa N Baranauskas1, John S Raglin1, Bernice A Pescosolido2, Brea L Perry2.
Abstract
Objectives: While organ-specific pathophysiology has been well-described in SARS-CoV-2 infection, less is known about the attendant effects on functional status, mood state and leisure-time physical activity (PA) in post-acute COVID-19 syndrome (PASC).Entities:
Keywords: SARS-CoV-2; functional capacity; long COVID; mental health; profile of mood states
Mesh:
Year: 2022 PMID: 35755951 PMCID: PMC9218064 DOI: 10.3389/ijph.2022.1604589
Source DB: PubMed Journal: Int J Public Health ISSN: 1661-8556 Impact factor: 5.100
Descriptives (n = 32) (Bloomington, IN, United States, 2022).
| Variables | SARS-CoV-2 | Controls |
| ES |
|---|---|---|---|---|
| Age (y) | 55 ± 11 | 54 ± 14 | 0.814 | |
| Height (m) | 1.64 ± 0.04 | 1.61 ± 0.07 | 0.263 | |
| Mass (kg) | 75 ± 20 | 67 ± 10 | 0.170 | |
| BMI (kg/m2) | 27.9 ± 7.0 | 25.9 ± 4.4 | 0.343 | |
| Body Fat (%) | 33.7 ± 7.4 | 32.1 ± 7.7 | 0.554 | |
| HR (bpm) | 71 ± 13 | 66 ± 8 | 0.167 | |
| SBP (mm Hg) | 126 ± 9 | 118 ± 11 | 0.051 | |
| DBP (mm Hg) | 82 ± 9 | 75 ± 7 | 0.031† | 0.78 |
| Rate-pressure product | 89 ± 17 | 77 ± 13 | 0.039† | 0.75 |
| PFSDQ-M [median (IQR)]‡ | 10 (14) | 2 (3) | 0.008† | 0.23 |
| Walking Self-Efficacy [median (IQR)] | 81 (44) | 95 (18) | 0.274 | |
| Leisure Score Index [median (IQR)] | 21 (18) | 36 (22) | 0.004† | 0.27 |
| Depression Medications (yes) [ | 6 (35) | 1 (7) | 0.051 | |
| Employed (yes) [ | 11 (65) | 11 (73) | 0.599 | |
| Marital Status [ | ||||
| Married or living with sig. other | 11 (65) | 11 (73) | 0.599 | |
| Education | ||||
| Bachelor’s Degree (yes) [ | 11 (65) | 13 (87) | 0.152 | |
| Annual Income [ | ||||
| ≥ $50k | 13 (76) | 12 (80) | 0.810 | |
Values are shown as means and SD unless noted otherwise. ES, effect size; BMI, body mass index; HR, heart rate; bpm, beats per min; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial blood pressure; mm Hg, millimeters per mercury; Rate-pressure product calculated by dividing the product of HR and SBP by 100. IQR, interquartile range. PFSDQ-M, pulmonary functional status and dyspnea questionnaire. ‡higher number indicative of greater disturbance. †Statistically significant between-group difference at p -value ≤0.050.
FIGURE 1Symptoms reported by SARS-CoV-2 participants (Bloomington, IN, United States, 2022). Footnote: The duration (days) and frequency (%) of symptoms reported after illness onset. Note the protracted duration in cough and joint/muscle aches.
Profile of mood states raw scores (n = 32) (Bloomington, IN, United States, 2022).
| POMS score | SARS-CoV-2 | Controls |
| ES |
|---|---|---|---|---|
| TMD | 19 ± 24 | −1 ± 12 | 0.005† | 1.0 |
| Tension [median (IQR)] | 7 (12) | 5 (4) | 0.009† | 0.9 |
| Depression [median (IQR)] | 3 (11) | 3 (3) | 0.262 | |
| Anger | 6 ± 5 | 3 ± 2 | 0.132 | |
| Vigor | 15 ± 6 | 20 ± 6 | 0.043† | 0.7 |
| Fatigue | 6 ± 6 | 4 ± 4 | 0.265 | |
| Confusion [median (IQR)] | 6 (4) | 3 (2) | 0.005† | 1.1 |
Values are shown as means and SD unless noted otherwise. POMS, profile of mood states; ES, effect size; TMD, total mood disturbance. IQR, interquartile range. †Statistically significant between-group differences at p-value ≤ 0.05.
FIGURE 2Profile of Mood States (POMS) sub-scale T-scores between SARS-CoV-2 and control participants (Bloomington, IN, United States, 2022). Footnote: *p < 0.05. ***p < 0.001. Means and 95% confidence intervals. Tension: SARS-CoV-2, 52.0 (47.9–57.0) vs. controls, 44.2 (41.6–46.8); Vigor: SARS-CoV-2, 44.4 (39.2–49.1) vs. controls, 51.4 (47.3–55.5); Confusion: SARS-CoV-2, 51.7 (48.0–56.3) vs. controls, 44.0 (41.9–46.6).
FIGURE 3(A) Unadjusted scatterplot between number of symptoms reported after illness onset and confusion T-score (Bloomington, IN, United States, 2022). (B) unadjusted scatterplot between functional status and number of days experiencing loss of taste/smell (Bloomington, IN, United States, 2022).